U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 10/577,714 Filing Date May 2, 2006 INFORMATION DISCLOSURE First Named Inventor Dharmarai Ramachandra Rao STATEMENT BY APPLICANT Art Unil 1614 (Use as many sheets as necessary) **Examiner Name** N/A PAC/eehc/23398US (4137-00900) Attorney Docket Number

Sheet

Examiner Initials*	Cite No.1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where	
	No.	Number-Kind Code <sup>2 (f known)</sup>	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
/C.B	/AA	<sup>US-</sup> 4,536,518	08/20/1985	Welch, Jr. et al.		
/C.B.	AB	<sup>US-</sup> 5,248,699	09/28/1993	Sysko, et al.		
/C.B./	AC	<sup>US-</sup> 5,734,083	03/31/1998	Wilson, et al.		
/C.B./	AD	<sup>US-</sup> 6,452,054 B2	09/17/2002	Aronhime, et al.		
/C.R/	AE	<sup>US-</sup> 6,495,721 B1	12/17/2002	Schwartz, et al.		
C.B.7	AF	<sup>US-</sup> 6,500,987 B1	12/31/2002	Schwartz, et al.		
/C.B./	AG	<sup>US-</sup> 6,517,866 B1	02/11/2003	Am Ende, et al.		
/C.B./	АН	<sup>US</sup> - 6,600,073 B1	07/29/2003	Schwartz, et al.		
/C.B./	Al	<sup>US-</sup> 6,858,652 B2	02/22/2005	Aronhime, et al.		
/C.E	,AJ	<sup>US-</sup> 2002/0183555 A1	12/05/2002	Schwartz, et al.		
C.B./	AK	<sup>US-</sup> 2003/0055112 A1	03/20/2003	Schwartz, et al.		
		US-				
		US-				
		US-				
		US-				
		US-			***************************************	
		US-				
		US-				
		US-				

		FORE	IGN PATENT DOCU	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (# known)	MM-DD-YYYY		Or Relevant Figures Appear	T <sup>6</sup>
/C.B./	BA	WO 01/32601 A1	05/10/2001	CIBA Specialty Chemicals Holding		
·/C.B.	/ BB	WO 01/45692 A1	06/28/2001	TEVA Pharmaceutical Industries Ltd		
/C.B./	вс	WO 03/093217 A1	11/13/2003	TEVA Pharmaceutical Industries Ltd		
		+870				
				,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	A-8-18-18-18-18-18-18-18-18-18-18-18-18-1	<u> </u>
						<u></u>

Examiner Signature	/Clinton Brooks/	Date Considered	03/23/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>8</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of Information Is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				Complete if Known		
Gubsiitu	(C 10/10/11/14-5//10			Application Number	10/577,714	
INF	ORMATION	DIS	CLOSURE	Filing Date	May 2, 2006	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Dharmaraj Ramachandra Rao	
				Art Unit	1614	
(Use as many sheets as necessary)			ecessary)	Examiner Name	N/A	
Sheet	2	of	2	Attorney Docket Number	PAC/eehc/23398US (4137-00900)	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/C.B./	CA	International Search Report and Written Opinion, PCT/GB2004/004672, May 17, 2005, 14 pgs.	
/C.B./	СВ	International Preliminary Report on Patentability, PCT/GB2004/004672, May 17, 2005, 11 pgs.	
/C.B./	СС	HALEBLIAN, JOHN K., et al., "Characterization of Habits and Crystalline Modification of Solids and Their Pharmaceutical Applications," Journal of Pharmaceutical Sciences, Vol. 64. No. 8, August 1975, pgs. 1269-1288.	
/C.B./	CD	ALMARSSON, ÖRN, et al., "High-Throughput Surveys of Crystal Form Diversity of Highly Polymorphic Pharmaceutical Compounds," XP-002295000, American Chemical Society, Crystal Growth & Design, Vol. 3, No. 6, 2003, pgs. 927-933.	,
/C.B./	CE	REMENAR, JULIUS F., et al., "Salt Selection and Simultaneous Polymorphism Assessment via High-Throughput Crystallization: The Case of Sertraline," American Chemical Society, Organic Process Research & Development, Vol. 7, No. 6, 2003, pgs. 990-996.	

Examiner	(0)( ) D	Date	03/23/2009
Signature	/Clinton Brooks/	Considered	3 3 3

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.